Jian‐Wu Yu

823 total citations
27 papers, 648 citations indexed

About

Jian‐Wu Yu is a scholar working on Epidemiology, Hepatology and Genetics. According to data from OpenAlex, Jian‐Wu Yu has authored 27 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 20 papers in Hepatology and 3 papers in Genetics. Recurrent topics in Jian‐Wu Yu's work include Hepatitis C virus research (18 papers), Liver Disease Diagnosis and Treatment (15 papers) and Hepatitis B Virus Studies (12 papers). Jian‐Wu Yu is often cited by papers focused on Hepatitis C virus research (18 papers), Liver Disease Diagnosis and Treatment (15 papers) and Hepatitis B Virus Studies (12 papers). Jian‐Wu Yu collaborates with scholars based in China, United States and Switzerland. Jian‐Wu Yu's co-authors include Lijie Sun, Shuchen Li, Peng Kang, Gui‐Qiang Wang, Yonghua Zhao, Xiaoguang Li, Philip Schoenfeld, William P. Forbes, Enoch Bortey and Anthony Lembo and has published in prestigious journals such as Journal of Hepatology, Clinical Pharmacology & Therapeutics and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Jian‐Wu Yu

25 papers receiving 621 citations

Peers

Jian‐Wu Yu
Elisabet Sánchez Spain
M.G. Swain United States
Mingshan Jiang China
Leticia Muñoz Spain
Eva Girona Spain
Tomoyuki Tsunoda Japan
Henry W. Kao United States
Christos Konstantakis Greece
Kui Chun Lam Hong Kong
Maria Cantera Spain
Elisabet Sánchez Spain
Jian‐Wu Yu
Citations per year, relative to Jian‐Wu Yu Jian‐Wu Yu (= 1×) peers Elisabet Sánchez

Countries citing papers authored by Jian‐Wu Yu

Since Specialization
Citations

This map shows the geographic impact of Jian‐Wu Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jian‐Wu Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jian‐Wu Yu more than expected).

Fields of papers citing papers by Jian‐Wu Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jian‐Wu Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jian‐Wu Yu. The network helps show where Jian‐Wu Yu may publish in the future.

Co-authorship network of co-authors of Jian‐Wu Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Jian‐Wu Yu. A scholar is included among the top collaborators of Jian‐Wu Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jian‐Wu Yu. Jian‐Wu Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Lijie, et al.. (2018). Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down‐regulation of silent information regulator 1. Journal of Medical Virology. 90(5). 926–935. 18 indexed citations
2.
Sun, Lijie, et al.. (2014). Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. International Journal of Infectious Diseases. 23. 75–81. 33 indexed citations
3.
Nguyen, Thi Huyen Tram, France Mentré, Micha Levi, Jian‐Wu Yu, & Jérémie Guedj. (2014). A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response. Clinical Pharmacology & Therapeutics. 96(5). 599–608. 8 indexed citations
4.
Schoenfeld, Philip, Mark Pimentel, Lin Chang, et al.. (2014). Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials. Alimentary Pharmacology & Therapeutics. 39(10). 1161–1168. 80 indexed citations
5.
Yu, Jian‐Wu, et al.. (2013). Inhibition of silent information regulator 1 induces glucose metabolism disorders of hepatocytes and enhances hepatitis C virus replication. Hepatology International. 7(2). 524–532. 3 indexed citations
6.
Yu, Jian‐Wu, et al.. (2013). Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1–AMPK signaling pathway. International Journal of Infectious Diseases. 17(7). e539–e545. 47 indexed citations
7.
8.
Yu, Jian‐Wu, et al.. (2012). The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. International Journal of Infectious Diseases. 16(6). e436–e441. 29 indexed citations
9.
Yu, Jian‐Wu, et al.. (2012). Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary & pancreatic diseases international. 11(2). 185–192. 14 indexed citations
10.
Yu, Jian‐Wu, et al.. (2011). Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment. International Journal of Infectious Diseases. 15(11). e740–e746. 18 indexed citations
11.
Yu, Jian‐Wu, et al.. (2011). Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver International. 31(4). 499–506. 25 indexed citations
12.
Li, Zhaoshen, et al.. (2011). [Establishment and application of nested real-time quantitative polymerase chain reaction assay for detection of hepatitis B virus covalently closed circular DNA].. PubMed. 25(4). 307–9. 1 indexed citations
13.
Yu, Jian‐Wu, et al.. (2011). The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C. European Journal of Gastroenterology & Hepatology. 23(12). 1192–1199. 5 indexed citations
14.
Yu, Jian‐Wu, et al.. (2011). [Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].. PubMed. 50(12). 1002–7. 1 indexed citations
15.
Yu, Jian‐Wu, Lijie Sun, Yonghua Zhao, et al.. (2009). Analysis of the efficacy of treatment with peginterferon α‐2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver International. 29(10). 1485–1493. 23 indexed citations
16.
Yu, Jian‐Wu, et al.. (2009). The Study of Efficacy of Lamivudine in Patients with Severe Acute Hepatitis B. Digestive Diseases and Sciences. 55(3). 775–783. 45 indexed citations
17.
Sun, Lijie, Jian‐Wu Yu, Yonghua Zhao, Peng Kang, & Shuchen Li. (2009). Influential factors of prognosis in lamivudine treatment for patients with acute‐on‐chronic hepatitis B liver failure. Journal of Gastroenterology and Hepatology. 25(3). 583–590. 65 indexed citations
18.
Yu, Jian‐Wu, Lijie Sun, Yonghua Zhao, & Shuchen Li. (2008). Prediction value of model for end‐stage liver disease scoring system on prognosis in patients with acute‐on‐chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. Journal of Gastroenterology and Hepatology. 23(8pt1). 1242–1249. 49 indexed citations
19.
Yu, Jian‐Wu, Gui‐Qiang Wang, Lijie Sun, Xiaoguang Li, & Shuchen Li. (2007). Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin. Journal of Gastroenterology and Hepatology. 22(6). 832–836. 104 indexed citations
20.
Yu, Jian‐Wu, Gui‐Qiang Wang, & Shuchen Li. (2006). Prediction of the prognosis in patients with acute‐on‐chronic hepatitis using the MELD scoring system. Journal of Gastroenterology and Hepatology. 21(10). 1519–1524. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabet Sánchez Breakdown of academic impact, for papers by M.G. Swain Breakdown of academic impact, for papers by Mingshan Jiang Breakdown of academic impact, for papers by Leticia Muñoz Breakdown of academic impact, for papers by Eva Girona Breakdown of academic impact, for papers by Tomoyuki Tsunoda Breakdown of academic impact, for papers by Henry W. Kao Breakdown of academic impact, for papers by Christos Konstantakis Breakdown of academic impact, for papers by Kui Chun Lam Breakdown of academic impact, for papers by Maria Cantera
Rankless by CCL
2026